PM — Q3 2026 Financial Report Analysis

Cigarette pricing carried the quarter; an investment-gain swing pulled reported EPS down

Philip Morris International (PMI) grew third-quarter 2026 net revenues 5.5% to $11.44 billion and operating income 14.1% to $4.87 billion, lifting its operating margin (the share of revenue left after running the business, before interest and tax) to 42.5% from 39.3%. Reported diluted earnings per share still fell 4.9%, to $2.12 from $2.23. The gap is below the operating line: PMI's investments and securities swung from $345 million of income a year ago to an $86 million loss, and the tax rate rose. On PMI's own adjusted measure, which strips out those items, EPS rose 5.4% to a record $2.36, well above the $2.20–$2.25 the company had guided for the quarter in July.

The engine was the old business. International cigarette shipments were flat, yet the combustibles segment raised prices 8.9% and grew revenue 7.8% organically ("organic" means excluding currency swings and acquisitions or disposals). Smoke-free products such as IQOS heated tobacco and ZYN nicotine pouches grew more slowly than cigarettes this quarter, 6.3% organically, so their share of revenue slipped slightly year on year.

This analysis is based on PMI's earnings release (Exhibit 99.1 to its October 21, 2026 Form 8-K) and the financial schedules filed with it (Exhibit 99.2). The full 10-Q for the quarter, with complete management discussion and cash-flow detail, had not been filed when this was written; PMI says it will follow "in the coming days."

Smoke-free share calculated from Exhibit 99.2's product-category schedule. Year-ago shipment volumes are given only as growth rates in the release.

Where the growth came from

International combustibles (cigarettes outside the U.S.): $6.73 billion revenue, +6.5% reported, +7.8% organic. Shipments were "broadly flat": growth in Turkey, Indonesia and Egypt offset declines in Russia, Poland and Japan. Pricing added $565 million, unfavourable geographic mix took away $75 million, and gross profit rose 9.8% organically. PMI's cigarette market share rose 0.4 points to 25.9%, and Marlboro reached a record 11.4% share. One caveat from the release: the quarter "also benefited from the favorable restructuring of distribution terms in certain markets, which is not expected to recur at the same level in future quarters." PMI does not quantify it.

International smoke-free: $3.87 billion revenue, +0.7% reported, +3.4% organic. This was the weak spot, and the reason is mostly timing. IQOS heated tobacco unit (HTU) shipments (the tobacco sticks heated in an IQOS device instead of burned) rose only 1.5%. Adjusted in-market sales (IMS), PMI's estimate of what retailers actually sold to consumers and the best guide to real demand, rose 7.1%. Shipments lagged demand because of what PMI calls "the phasing of shipments between periods, notably in Japan." Outside Japan and Poland, HTU in-market sales grew 10%.

• Japan: HTU in-market sales rose 3.4%, but only 1.3% excluding estimated "pantry-loading" (consumers stocking up) before the October 1 excise-driven price increase of JPY20 per pack. That followed a JPY40 rise on April 1. IQOS kept a 68% share of the heated-tobacco category.
• Europe: HTU in-market sales rose about 6.0%, or about 8% excluding Poland, where a ban on characterizing flavours is still hurting. IQOS share rose 0.9 points to 11.6%.
• Elsewhere: in-market sales rose 12.7%.
• E-vapor (VEEV): shipments rose 61.6% to 1.4 billion units, from a small base.
• International oral (ZYN and Nordic snus): volume turned positive at +0.5%. Modern pouches grew 20.6% to 0.5 billion, offsetting declines in legacy snus.

U.S.: $845 million revenue, +22.7%. ZYN shipments rose 4.2% to 3.2 billion pouches even against a year-ago quarter boosted by a special promotional campaign. The revenue jump comes partly from that comparison: last year's promotions depressed prices, so this year's pricing looks better. U.S. smoke-free revenue rose 25.2% to $758 million. Operating companies income (OCI, PMI's segment-level operating profit) fell 3.3% reported, or rose 1.5% organically, to $171 million on an adjusted basis, "including a significant increase in commercial investments" behind new ZYN ULTRA, dry-flavour and 1.5mg/8mg products. In August the FDA authorized 11 ZYN ULTRA variants, bringing ZYN to 31 authorized variants.

Currency: a stronger dollar cut $155 million (about 1.4 points) from quarterly revenue growth but only 1 cent from adjusted EPS, because cost-side currency effects largely offset it. Over nine months, currency has been a tailwind: +$734 million in revenue and +$0.20 in adjusted EPS.

What the headline numbers hide

• Reported EPS fell for non-operating reasons. PMI's own EPS bridge for the quarter: operations added $0.19 per share and lower interest $0.02, while a higher tax rate cost $0.08 and currency $0.01. The rest of the move from $2.23 to $2.12 is adjusting items. These include a $0.06 hit from the falling share prices of PMI's passive stakes in listed companies in India and Sri Lanka (a year ago the same line was a $0.07 gain), a $0.04 loss on buying out a Dutch pension plan, and the absence of last year's $0.10 Canada (RBH) settlement income and $0.14 of tax benefits. None of these is cash from selling products.
• Operating income growth is flattered by last year's charges. Reported operating income rose 14.1%, but adjusted operating income rose 9.6%. The gap is a $156 million smaller adjustments bill: last year's quarter carried a Germany excise-tax litigation charge and other items. Organic operating income growth of 10.5% is the cleanest underlying figure.
• Tax was a headwind, not a help. The reported effective tax rate was 21.5% ($986 million on $4,594 million of pre-tax earnings), up from 18.7%. PMI's EPS bridge puts the rate change at −$0.08 per share.
• No help from buybacks. Diluted shares were 1,560 million, against 1,558 million a year ago, and PMI's guidance assumes no repurchases. All of the adjusted EPS growth came from the business.
• Cash conversion is strong. Nine-month operating cash flow was $10.45 billion, against net earnings of $9.09 billion and $7.52 billion of operating cash flow a year earlier. The quarter alone produced $5.35 billion. As our Q2 analysis noted, much of the first-half improvement came from lower working capital (money tied up in inventory and receivables); the Q3 cash-flow statement that would show whether that continued will be in the 10-Q.
• Debt is coming down. Net debt (total debt minus cash) fell to $40.9 billion from $44.0 billion at year-end. That is 2.17 times trailing adjusted EBITDA (a rough measure of cash operating profit), down from 2.53 times, against a target of close to 2.0 times by year-end. Short-term borrowings rose to $2.53 billion from $168 million, while long-term debt fell to $41.7 billion from $45.1 billion.
• One quality flag in combustibles. Part of the 7.8% organic combustibles growth came from the one-off distribution-terms restructuring, which PMI says won't recur at the same level. Without an amount, the size of the underlying combustibles pricing gain is somewhat overstated by an unknown margin.

Did last time's read hold up?

Our Q2 report flagged two things to watch. First, guidance needed second-half acceleration: first-half organic revenue growth of 5.3% sat at the bottom of the 5%–7% full-year range, and organic operating income growth of 6.1% sat below the 7%–9% range. That happened in Q3. Organic revenue grew 7.1% and organic operating income 10.5%, lifting the nine-month figures to 5.9% and 7.7%, both now inside the ranges. Second, we called U.S. ZYN share loss the real risk. ZYN gained more than a point of share between June and September, but PMI paid for it in profit: U.S. operating income fell 3.3% on a revenue increase of 22.7%, and more spending is coming in Q4. The share risk eased; the margin cost of defending share is now visible.

Takeaway: Cigarettes, not smoke-free products, carried this quarter. Price increases of 8.9% on flat volume delivered most of the 10.5% organic operating income growth, while smoke-free revenue grew 6.3% organically and slipped to 40.4% of the total. The smoke-free story still holds on consumer demand (HTU in-market sales +7.1%), but this quarter's profit beat was paid for by the business PMI says it wants to phase out.

Guidance and outlook

PMI kept its underlying outlook and changed the headline numbers for currency only. Adjusted diluted EPS guidance is now $8.29–$8.44, 9.9%–11.9% growth on 2025's $7.54, up from $8.26–$8.41 in July. The range includes a $0.18 currency tailwind (July's release assumed $0.15; today's release says "previously $0.24"). Excluding currency, the range is unchanged at $8.11–$8.26, or 7.5%–9.5% growth. Reported EPS guidance fell to $7.11–$7.26 from $7.19–$7.34 because full-year adjusting items grew to $1.18 per share (from $1.07 implied by July's ranges), including the $0.22 equity-investment fair-value loss and the $0.04 Dutch pension buy-out.

Within that range, PMI shifted its emphasis:

• Volume: total shipments are now expected to grow (previously "broadly stable to slightly growing"). The cigarette decline should be similar to the year-to-date −1.2%, better than the 2%–3% decline assumed before.
• Revenue: organic growth of 5%–7%, "with a greater likelihood to be in the middle or upper-half," helped by a fourth-quarter reacceleration in international smoke-free as Japan's shipment phasing reverses.
• Profit: organic operating income growth of 7%–9%, but now "with a greater likelihood to be in the middle or lower-half." Two reasons are given: energy-related input costs linked to the Middle East conflict, expected to bite harder in Q4, and a further step-up in U.S. ZYN investment. That includes moving most flagship ZYN to 20-pouch cans from 15, with transitional support programs.
• Other assumptions: operating cash flow around $13.5 billion, capital spending of $1.4–$1.6 billion, net debt to EBITDA close to 2.0x, no share repurchases. The quarterly dividend rises 8.8% to $1.60 ($6.40 a year).

Our read: the guidance language tells you where Q4 is heading. Revenue lands in the upper half and profit in the lower half, so margins in Q4 grow less than in Q3. A nine-month organic operating income growth of 7.7% against a full-year range whose midpoint is 8% leaves little room. Q4 has to absorb higher U.S. marketing, the can-size transition and energy costs, while losing at least part of this quarter's one-off distribution benefit. What to watch in the Q4 release: whether international HTU shipments catch up with in-market sales as promised (Q3: +1.5% vs +7.1%), and whether U.S. ZYN's share gains hold once the 20-pouch can changes the price per pouch. If both happen, smoke-free growth should overtake cigarettes again. If not, 2026's earnings growth will have depended more on cigarette pricing than PMI's strategy implies.